Sylvester Comprehensive Cancer Center is building a dedicated Myeloma Research Institute. C. Ola Landgren, who joined Sylvester two years ago, will be the director.
Alessandro Fatatis was named associate director for basic research at Jefferson Health’s Sidney Kimmel Cancer Center.
Robert W. Sobol was named associate director for basic research and co-leader of the Cancer Biology Program at the Legorreta Cancer Center at Brown University. In this role, he leads efforts toward continued growth of the basic science program and will serve as the co-leader of the Cancer Biology Program. He is also a professor of pathology and laboratory medicine.
Sendurai A. Mani has been named associate director for translational oncology at the Legorreta Cancer Center at Brown University and professor of pathology and laboratory medicine.
Medicine in the Media, a free, in-person, four-day workshop held in Washington, DC to help journalists hone their skills in reporting on medical research, is open to applications.
The American Society of Hematology named Chancellor Donald, of Tulane University, Cynthia E. Dunbar, of NIH, Stephanie Lee, of Fred Hutchinson Cancer Center, and Laura Michaelis, of Medical College of Wisconsin, recipients of the 2022 Exemplary Service Award for their exceptional service and dedication to the Society and the field of hematology through their tireless work leading ASH’s response to COVID-19.
The American Society of Hematology named physician Keith Hoots, and Sens. Jacky Rosen (D-NV), John Barrasso (R-WY), and Tammy Baldwin (D-WI) recipients of the 2022 ASH Advocacy Awards for their outstanding advocacy for hematology research and clinical care.
The American Society of Hematology elected four new members to its executive committee for terms beginning after the 2022 ASH Annual Meeting, Dec. 10-13 in New Orleans.
Psychologist Lauren A. Rosenberg was named assistant clinical professor in the Section of Psychiatry at Fox Chase Cancer Center.
Results from the RIGHT Choice phase II trial showed that Kisqali (ribociclib) plus endocrine therapy demonstrated a nearly one-year PFS benefit for patients with aggressive breast cancer.
